Baird Downgrades Synageva BioPharma (GEVA) to Neutral
Tweet
Share
E-mailGet Alerts GEVA Hot Sheet
Price: $238.60 --0%
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 5
Rating Summary:
6 Buy, 7 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 10 | Down: 8 | New: 5
Join SI Premium – FREE
Baird downgraded Synageva BioPharma (NASDAQ: GEVA) from Outperform to Neutral with a price target of $217.00 (from $115.00).
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $203.39 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- ICICI Securities Downgrades Landmark Cars (LANDMARK:IN) to Add (2)
- Lenskart Solutions (LENSKART:IN) PT Raised to INR615 at Kotak
- Wolfe Research Downgrades Stryker (SYK) to Peerperform
Create E-mail Alert Related Categories
Analyst PT Change, DowngradesRelated Entities
Robert W BairdSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
